CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $40.07 million. The enterprise value is $15.13 million.
| Market Cap | 40.07M |
| Enterprise Value | 15.13M |
Important Dates
The last earnings date was Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 15.12 million shares outstanding. The number of shares has increased by 8.40% in one year.
| Current Share Class | 15.12M |
| Shares Outstanding | 15.12M |
| Shares Change (YoY) | +8.40% |
| Shares Change (QoQ) | +10.65% |
| Owned by Insiders (%) | 25.94% |
| Owned by Institutions (%) | 11.58% |
| Float | 9.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 120.94 |
| Forward PS | 69.88 |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 45.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.57
| Current Ratio | 8.57 |
| Quick Ratio | 8.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -107.62% and return on invested capital (ROIC) is -69.07%.
| Return on Equity (ROE) | -107.62% |
| Return on Assets (ROA) | -60.80% |
| Return on Invested Capital (ROIC) | -69.07% |
| Return on Capital Employed (ROCE) | -135.73% |
| Weighted Average Cost of Capital (WACC) | -19.44% |
| Revenue Per Employee | $22,086 |
| Profits Per Employee | -$2.02M |
| Employee Count | 15 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.97% in the last 52 weeks. The beta is -4.31, so CervoMed's price volatility has been lower than the market average.
| Beta (5Y) | -4.31 |
| 52-Week Price Change | -70.97% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 4.83 |
| Relative Strength Index (RSI) | 44.11 |
| Average Volume (20 Days) | 373,338 |
Short Selling Information
The latest short interest is 832,425, so 5.51% of the outstanding shares have been sold short.
| Short Interest | 832,425 |
| Short Previous Month | 827,455 |
| Short % of Shares Out | 5.51% |
| Short % of Float | 8.67% |
| Short Ratio (days to cover) | 1.53 |
Income Statement
In the last 12 months, CervoMed had revenue of $331,295 and -$30.35 million in losses. Loss per share was -$3.19.
| Revenue | 331,295 |
| Gross Profit | -21.50M |
| Operating Income | -31.16M |
| Pretax Income | -30.35M |
| Net Income | -30.35M |
| EBITDA | n/a |
| EBIT | -31.16M |
| Loss Per Share | -$3.19 |
Balance Sheet
The company has $24.94 million in cash and no debt, with a net cash position of $24.94 million or $1.65 per share.
| Cash & Cash Equivalents | 24.94M |
| Total Debt | n/a |
| Net Cash | 24.94M |
| Net Cash Per Share | $1.65 |
| Equity (Book Value) | 22.96M |
| Book Value Per Share | 1.70 |
| Working Capital | 22.96M |
Cash Flow
| Operating Cash Flow | -27.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -27.98M |
| FCF Per Share | -$1.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | -9,406.96% |
| Pretax Margin | -9,160.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.40% |
| Shareholder Yield | -8.40% |
| Earnings Yield | -75.75% |
| FCF Yield | -69.83% |
Analyst Forecast
The average price target for CervoMed is $15.40, which is 481.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.40 |
| Price Target Difference | 481.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of 2.74 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.74 |
| Piotroski F-Score | 2 |